Keywords: PBTK model; Toxicokinetics; Fish; Internal dose; ADME;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Transdermal delivery; Pharmacokinetic simulation; Model sensitivity; Administration route; ADME; Melatonin;
Keywords: ADME; absorption, distribution, metabolism and excretion; AUC; area under the blood/plasma concentration time curve; BMDL; lower 95% confidence limit of the benchmark dose; Cmax; maximum blood/plasma concentration; NOAEL; no-observed-adverse-effect-level;
Keywords: MD; Mediterranean diet; HT; hydroxytyrosol; IUPAC; International Union of Pure and Applied Chemistry; ADME; absorption, distribution, metabolism and excretion processes; EVOO; extra virgin olive oil; HTA; HT acetate; Tyr; tyrosol; EFSA; European Food Safe
Keywords: Acute inhalation toxicity; In vitro; In silico; Ex vivo; Quantitative structure-activity relationships (QSAR); Adverse outcome pathway; Aggregate exposure pathway; Dosimetry; Integrated approach to testing and assessment (IATA); Risk assessment; ADME; abs
Keywords: NTM; nontuberculous mycobacteria; Mtb; Mycobacterium tuberculosis; SAR; structure activity relationship; Mbs; Mycobacterium abscessus ATCC 19977; MIC; minimum inhibitory concentration; RHS; right hand side; LHS; left hand side; ADME; absorption, distribut
Keywords: ADME; absorption, distribution, metabolism and excretion; AFND; allele frequency net database; ALT; alanine aminotransferase; AOP; adverse outcome pathway; AOP-KB; AOP knowledge base; AST; aspartate aminotransferase; BSEP; bile salt export protein; CAR; c
Keywords: Arg-Gly-Asp; Arginylglycylaspartic acid; FDA; Food and Drug Administration; DNA; Deoxyribonucleic acid; NCI; National Cancer Institute; SCLC; Small cell lung cancers; NSCLC; Non-small cell lung cancers; 5-FU; 5-Fluorouracil; OTCs; Organic cationic transpo
Keywords: ADME; Botanical dietary supplements; Ginkgo biloba extract; Poly-pharmacokinetics; Pharmacokinetics; Toxicokinetics; Botanical-drug interaction;
Keywords: ADME; absorption distribution metabolism elimination; ASEs; aerosols solvent extractions; AUC; area under curve; BBB; blood-brain barrier; BCS; Biopharmaceutical Classification System; BDP; beclomethasone dipropionate; CFC; critical flocculation concent
Keywords: Anticancer drug; Metabolites; Adverse drug reactions; Toxicity; ADME;
Keywords: Dihydroquinoline; Friedländer synthesis; Sodium trifluoromethanesulfonate; Anti-tubercular activity; ADME;
Keywords: ADME; Absorption, Distribution, Metabolism, Excretion; AOPs; adverse outcome pathways; AUC; Area under the Curve; AEs; assessment elements; AOs; assessment options; BMDL; benchmark dose lower bound; CAAT; Center for Alternatives to Animal Testing; Cefic-L
Keywords: Nonclinical; Small molecules; Biopharmaceuticals; Monoclonal antibodies; Pharmacology; ADME; Pharmacokinetics; Toxicology; Clinical starting dose; Investigator Brochure;
Keywords: ADME; absorption distribution metabolism excretion; AFE; average fold error; CLint; intrinsic metabolic clearance; CRO; contract research organisation; CYP; cytochrome P450; DMPK; drug metabolism and pharmacokinetics; G6P; glucose-6-phosphate; t1/2; half-
Keywords: Maximum tolerated dose; Chronic toxicity; Carcinogenicity; Toxicokinetics; Gender difference; ADME; absorption, distribution, metabolism, and excretion; AUCs; areas under the curve; Cmax; maximum concentration; KMD; kinetically-derived maximum dose; MTD;
Quantitative estimation of cholinesterase-specific drug metabolism of carbamate inhibitors provided by the analysis of the area under the inhibition-time curve
Keywords: AChE; acetylcholinesterase (EC 3.1.1.7); ADME; absorption, distribution, metabolism, excretion; AUC; area under the concentration-time curve; AUIC; area under the inhibition-time curv; BChE; butyrylcholinesterase (EC 3.1.1.8); BTCh; butyrylthiocholine; DT
Pharmacokinetics, tissue distribution and excretion of luteolin and its major metabolites in rats: Metabolites predominate in blood, tissues and are mainly excreted via bile
Keywords: Luteolin; Metabolite; Pharmacokinetics; Bioavailability; Distribution; Excretion; ADME; absorption, distribution, metabolism and excretion; AUC; area under the curve; BCRP; breast cancer resistance protein; CE; collision energy; Cmax; peak concentration;
Design, synthesis, chemical and biological evaluation of brain targeted alkylating agent using reversible redox prodrug approach
Keywords: Alkylating agent; Blood-brain barrier; Redox system; ADME; NBP assay; Biological oxidation;
Keywords: GK; Glucokinase; GKA; glucokinase activators; QSAR; Quantitative Structure Activity Relationship; RMSE; root mean square error; RMSD; root mean square devaition; ADME; absorption, distribution, metabolism, and excretion; IR; infra red; NMR; nuclear magnet
Keywords: Tuberculosis; Cell wall permeability; Drug-like properties; In silico; ADME; Physiochemical parameters;
Keywords: SACP; simulated annealing of chemical potential; CFA; constrained fragment analysis; FE Pred; predicted relative free energy; ÎÎGs; relative solvation change; D5W; 5% dextrose (glucose) in water; Vdss; steady-state volume of distribution; Cl; clearance;
Keywords: ADME; absorption, distribution, metabolism, and excretion; AUC; area under concentration-time curve; BCRP; breast cancer resistance protein; BSEP; bile salt export pump; CFTR; cystic fibrosis transmembrane conductance regulator; Cmax; maximal plasma conce
Keywords: ADME; clinical pharmacokinetics; drug interactions; membrane transporter; organic cation transporters; pharmacogenomics; pharmacokinetics/pharmacodynamics;
Keywords: PCP; physicochemical properties; Ro5; Lipinski rule of five; PCA; principal component analysis; AlogP; partition coefficient; GABA; gamma-aminobutyric acid; PSA; polar surface area; MR; molecular refractivity; QED; quantitative estimate of drug-likeness;
Keywords: albumin; mathematical model; pharmacokinetics; protein binding; organic anion-transporting polypeptide transporters; food effects; hepatic transport; nonlinear pharmacokinetics; clinical pharmacokinetics; ADME; BA; bioavailability; BCS; biopharmaceutica
Keywords: ADME; biotechnology; clinical pharmacokinetics; excipients; immune response;
Keywords: AD; Alzheimer disease; ADME; absorption, distribution, metabolism and excretion; AO; adverse outcome; AOP; adverse outcome pathway; AOP-KB; adverse outcome pathway knowledge base; BDNF; brain derived neurotrophic factor; B/H; Bradford-Hill; CI; complex I
Keywords: biliary excretion; hepatocytes; ADME; hepatobiliary disposition; cell culture; tissue engineering; toxicology; membrane transport/transporters; disposition; metabolism; 3D; 3-dimensional; 3D-HLT; 3D-bioprinted human liver tissue; APAP; acetaminophen; DMPK
Keywords: Nanosuspension; Safety; Nanotoxicology; Sterilization; Drug delivery; NCEs; new chemical entities; MTD; maximum tolerated doses; IV; intravenous; MPS; mononuclear phagocyte system; EPR; enhanced permeability and retention; HPMC; hydroxy propyl methyl cell
Keywords: oral drug delivery; gastrointestinal transit; Biopharmaceutics Classification System; oral absorption; ADME; in vitro models; in vitro/in vivo correlations;
Keywords: ADME; pediatric; physiologically based pharmacokinetic modeling; biopharmaceutics classification system; solubility;
Keywords: ADME; adsorption distribution metabolism excretion; AGG; amine-generating group; CDK; chemistry development kit; EDG; electron donating group; EPA; Environmental Protection Agency; EWG; electron-withdrawing group; FN; false negative; FP; false positive; G
Keywords: Alprenolol (PubChem CID: 2119); Atenolol (PubChem CID: 2249); Cyclosporin A (PubChem CID: 5,284,373); Doxorubicin (PubChem CID: 31,703); Gentamicin (PubChem CID: 3467); Metoprolol (PubChem CID: 4171); Pindolol (PubChem CID: 4828); Rifampicin (PubChem CID:
Keywords: Risk assessment; Less than lifetime exposure; Fluctuating exposure; Intermittent exposure; ADME; absorption, distribution, metabolism and excretion; AUC; area under the blood/plasma concentration time curve; BMDL; lower 95% confidence limit of the benchma
Keywords: ADME; Immunomodulatory peptides; Data mining; Gene Ontology; Crop plants;
Keywords: Advanced therapy medicinal products; Cell therapy; Clinical trials; Marketing authorisation; Preclinical testing; Tumourigenicity; ADME; Absorption, distribution, metabolism & excretion; MHRA; Medicines & Healthcare products Regulatory Agency; WHO; World
Keywords: irregular sampling; Fisher information matrix; dynamic systems; pharmacokinetic time sampling; Pharmacokinetics/pharmacodynamics; Computational; ADME; Dynamic simulation; Dose-response; Clinical pharmacokinetics;
Keywords: ADME; blood-brain barrier; computational ADME; drug transport; unbound brain-to-plasma concentration ratio; machine learning; in silico modeling;
Keywords: ADME; clearance; disposition; drug safety; hepatocytes; IVIVEs; isolated perfused liver; PKPD; pharmacokinetics; pharmacodynamics;
Keywords: pharmacokinetics; ADME; transporters; CYP enzymes; P-glycoprotein; microsomal stability
Keywords: PK; pharmacokinetics; GI; gastrointestinal; GET; gastric emptying time; OCTT; oro-cecal transit time; SITT; small intestinal transit time; LITT; large intestinal transit time; TTT; total transit time; MTTT; mean total transit time; ADME; absorption, metab
Keywords: ADME; bioavailability; biopharmaceutics classification system (BCS); clinical pharmacokinetics; clearance; formulation; oral absorption; physiological model; preclinical pharmacokinetics; solubility
Keywords: 5α-R; 5α-reductase type 2; ADME; absorption, distribution, metabolism and excretion; AG; andrographolide; AGD; anogenital distance; AOP; adverse outcome pathway; AR; androgen receptor; BPAD; biological pathway altering dose; CHH; congenital hypogonadotr
Keywords: CYP; cytochrome P-450; GSH-transferase; glutathione-S-transferase; UDP-glucuronosyltransferase; uridine 5â²-diphospho-glucuronosyltransferase; EGb761®; Ginkgo biloba extract, CAS 122933-57-7; AhR; aryl hydrocarbon receptor; PXR; pregnane X receptor; CAR
Keywords: Pharmacokinetics; Phytoconstituents; Traditional Chinese medicines (TCM); Traditional medicinal systems (TMS); ADME
Keywords: ADME; absorption, distribution, metabolism, elimination; ANOVA; analysis of variance; BCR; B cell receptor; BN; Brown Norway; BSA; bovine serum albumin; EAR; early asthmatic response; ELISA; enzyme-linked immunosorbent assay; FBS; fetal bovine serum; IC50
Keywords: ADME; absorption/distribution/metabolism/excretion; BBB; blood-brain barrier; CD3OD; tetradeuteromethanol; CDCl3; deuterochloroform; CH2Cl2; dichloromethane; C log D; distribution coefficient; C log P; calculated partition coefficient; CNS; central
Keywords: DPPS; dipalmitoylphosphatidylserine; DPPC; dipalmitoylphosphatidylcholine; CMC; critical micellar concentration; PAMPA; Parallel Artificial Membrane Permeability Assay; PLD; Drug-induced phospholipidosis; CADs; Cationic amphiphilic drugs; PLD+; phospholip
Keywords: ADME; absorption, distribution, metabolism, excretion; BBB; blood-brain barrier; CEV; California encephalitis virus; CNS; central nervous system; CPE; cytopathic effect; ECMV; encephalomyocarditis virus; fLUC; firefly luciferase; FMV; Fort Morgan virus;